Dr Reddy's Laboratories announces commercial launch of Covid-19 drug 2-DG

Dr. Reddy's Laboratories Ltd on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG).

According to a press release issued by the city-based drug maker, Dr. Reddy's will supply the drug to major government as well as private hospitals across India.

In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of the country.

2-DG manufactured by Dr. Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG.

The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to Government institutions, it said.

2-DG, a oral drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's.

Dr. G Satheesh Reddy, Secretary, Department of Defence (R&D) and Chairman, DRDO said "We are pleased to have worked closely with our long-term industry partner Dr. Reddy's Laboratories, Hyderabad, for testing 2-DG as therapeutic application in treatment of COVID-19 patients. DRDO has been contributing in the fight against COVID-19 pandemic with its spin off technologies."

It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.

Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.

Satish Reddy, Chairman, Dr. Reddy's, said "2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel